Scancell Holdings plc (FRA:SCP)
Germany · Delayed Price · Currency is EUR | Market Cap | 137.67M +32.6% |
| Revenue (ttm) | 5.36M |
| Net Income | -6.28M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 1,114 |
| Open | 0.1010 |
| Previous Close | 0.1010 |
| Day's Range | 0.1010 - 0.1010 |
| 52-Week Range | 0.0570 - 0.1850 |
| Beta | n/a |
| RSI | 44.07 |
| Earnings Date | Jan 23, 2026 |
About Scancell Holdings
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody for the treatment of small cell lung cancer. It also develops Modi-1, an active peptide immunotherapy that is in phase II clinical trials for the treatment of solid tumors, including renal, head and neck, ovarian and triple negative breast cancers; and Modi-2, which targ... [Read more]
News
Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma
Unlocks path towards registrational Phase 3 trial planned to start in 2026 Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine standard of care (SoC) iSCIB1+ shows an interim 24%-poin...
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, today announces a b...
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety
PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet and Scancell agreement builds on PharmaJet's strategy to be the best-in-class delivery system for novel DNA and RNA cancer immunotherapies.
PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free
GOLDEN, Colo.--(BUSINESS WIRE)--Positive data announced for first stage of Phase 2 trial for advanced melanoma DNA vaccine delivered by the PharmaJet Stratis needle-free system.